SEC Comment Letter 0000000000-23-007819 to MARIZYME, INC. (MRZM) (CIK 0001413754)
MARIZYME, INC. (MRZM) (CIK 0001413754)
Date: July 21, 2023 · CIK: 0001413754 · Accession: 0000000000-23-007819
AI Filing Summary & Sentiment
File numbers found in text: 333-273308
Letter
United States securities and exchange commission logo July 21, 2023 David Barthel Chief Executive Officer Marizyme, Inc. 555 Heritage Drive, Suite 205 Jupiter, Florida 33458 Re:Marizyme, Inc. Registration Statement on Form S-1 Filed July 18, 2023 File No. 333-273308 Dear David Barthel: We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Registration Statement on Form S-1 filed July 18, 2023 General 1.We note that you are registering the resale of up to 754,670,238 shares of common stock. However, we note from your disclosure on page 2 that you currently have 300,000,000 shares of common stock authorized at this time. Please either revise so that the volume of common stock registered in the resale offering does not exceed the number of shares of common stock that remain available for issuance at the time you anticipate having the registration statement declared effective or revise to update your disclosure once the Capital Event Amendment referenced on page 2 has been approved by your stockholders. For guidance, refer to Staff Legal Bulletin No. 19 Section II.B.1.a.
FirstName LastNameDavid Barthel Comapany NameMarizyme, Inc. July 21, 2023 Page 2 FirstName LastName David Barthel Marizyme, Inc. July 21, 2023 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Tim Buchmiller at (202) 551-3635 or Laura Crotty at (202) 551-7614 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Louis A. Bevilacqua, Esq.
Show Raw Text
United States securities and exchange commission logo
July 21, 2023
David Barthel
Chief Executive Officer
Marizyme, Inc.
555 Heritage Drive, Suite 205
Jupiter, Florida 33458
Re:Marizyme, Inc.
Registration Statement on Form S-1
Filed July 18, 2023
File No. 333-273308
Dear David Barthel:
We have limited our review of your registration statement to those issues we have
addressed in our comments. In some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Registration Statement on Form S-1 filed July 18, 2023
General
1.We note that you are registering the resale of up to 754,670,238 shares of common stock.
However, we note from your disclosure on page 2 that you currently have 300,000,000
shares of common stock authorized at this time. Please either revise so that the volume of
common stock registered in the resale offering does not exceed the number of shares of
common stock that remain available for issuance at the time you anticipate having the
registration statement declared effective or revise to update your disclosure once the
Capital Event Amendment referenced on page 2 has been approved by your stockholders.
For guidance, refer to Staff Legal Bulletin No. 19 Section II.B.1.a.
FirstName LastNameDavid Barthel
Comapany NameMarizyme, Inc.
July 21, 2023 Page 2
FirstName LastName
David Barthel
Marizyme, Inc.
July 21, 2023
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Tim Buchmiller at (202) 551-3635 or Laura Crotty at (202) 551-7614 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Louis A. Bevilacqua, Esq.